Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Jastaniyah, Noha ^a   Murtha, Albert ^a   Pervez, Nadeem ^a   Le, Duc ^a   Roa, Wilson ^a   Patel, Samir ^a   Mackenzie, Marc ^a   Fulton, Dorcas ^a   Field, Colin ^a   Ghosh, Sunita ^a   Fallone, Gino ^a   Abdulkarim, Bassam ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Concurrent RT and TMZ; GBM; Hypofractionation; IMRT; Phase I study

Indexed keywords

COTRIMOXAZOLE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLINDNESS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GROSS TUMOR VOLUME; HUMAN; HUMAN TISSUE; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECURSIVE PARTITIONING ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VOLUME;

EID: 84873970909     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-38     Document Type: Article

References (17)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009.
2. Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004, 58(3):721-726. 10.1016/S0360-3016(03)01623-7, 14967426.
3. Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 2004, 58(1):247-252. 10.1016/S0360-3016(03)00819-8, 14697445.
4. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009, 73(2):473-478. 10.1016/j.ijrobp.2008.04.030, 18554821.
5. Fenwick JD, Tome WA, Soisson ET, Mehta MP, Rock MT. Tomotherapy and other innovative IMRT delivery systems. Semin Radiat Oncol 2006, 16(4):199-208. 10.1016/j.semradonc.2006.04.002, 17010902.
6. Thomas SD, Mackenzie M, Field GC, Syme AM, Fallone BG. Patient specific treatment verifications for helical tomotherapy treatment plans. Med Phys 2005, 32(12):3793-3800. 10.1118/1.2134929, 16475779.
7. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9(5):453-461. 10.1016/S1470-2045(08)70125-6, 18452856.
8. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85(9):704-710. 10.1093/jnci/85.9.704, 8478956.
9. Hulshof MC, Schimmel EC, Andries Bosch D, Gonzalez Gonzalez D. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000, 54(2):143-148. 10.1016/S0167-8140(99)00183-8, 10699477.
10. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-Demasters BK, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011, 81(4):1066-1074. 10.1016/j.ijrobp.2010.07.021, 20932651.
11. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003, 63(3):263-270. 10.1023/A:1024217527650, 12892232.
12. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007, 9(1):47-52. 1828105, 17108062.
13. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994, 30(2):146-149. 10.1016/0167-8140(94)90044-2, 8184112.
14. Garden AS, Maor MH, Yung WK, Bruner JM, Woo SY, Moser RP, et al. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 1991, 20(2):99-110. 10.1016/0167-8140(91)90143-5, 1851573.
15. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 2009, 27(8):1275-1279. 10.1200/JCO.2008.19.4969, 19188675.
16. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26(13):2192-2197. 10.1200/JCO.2007.14.8163, 18445844.
17. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010, 37(1):36-42.